3 However, the recommendations were based on small-size randomised controlled trials (RCTs) with borderline significance or uncontrolled open-label studies. 3 To our knowledge, this is the first prospective study to investigate the efficacy and safety of baricitinib in refractory TAK patients.
← all excerpts
Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.
1
—
—